|Report ID : RC-4933||Category : Pharmaceuticals||Published Date : Jan-2019|
|Publisher : S-AND-P||Pages : 117||Format : PDF|
This report studies the global market size of Biosimilars in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilars in these regions. This research report categorizes the global Biosimilars market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis. In 2017, the global Biosimilars market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Biosimilars market based on company, product type, application and key regions. The various contributors involved in the value chain of Biosimilars include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Biosimilars include Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis Market Size Split by Type Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin) Peptides (Glucagon, Calcitonin) Market Size Split by Application Oncology Blood Disorders Market size split by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Biosimilars market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. To understand the structure of Biosimilars market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Biosimilars manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Biosimilars with respect to individual growth trends, future prospects, and their contribution to the total market. To project the value and volume of Biosimilars submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies. In this study, the years considered to estimate the market size of Biosimilars are as follows: History Year: 2013-2017 Base Year: 2017 Estimated Year: 2018 Forecast Year 2018 to 2025 This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biosimilars market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Biosimilars Product 1.2 Key Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Biosimilars Market Size Growth Rate by Type 1.4.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) 1.4.3 Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin) 1.4.4 Peptides (Glucagon, Calcitonin) 1.5 Market by Application 1.5.1 Global Biosimilars Market Size Growth Rate by Application 1.5.2 Oncology 1.5.3 Blood Disorders 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Biosimilars Market Size 2.1.1 Global Biosimilars Revenue 2016-2025 2.1.2 Global Biosimilars Sales 2016-2025 2.2 Biosimilars Growth Rate by Regions 2.2.1 Global Biosimilars Sales by Regions 2.2.2 Global Biosimilars Revenue by Regions 3 Breakdown Data by Manufacturers 3.1 Biosimilars Sales by Manufacturers 3.1.1 Biosimilars Sales by Manufacturers 3.1.2 Biosimilars Sales Market Share by Manufacturers 3.1.3 Global Biosimilars Market Concentration Ratio (CR5 and HHI) 3.2 Biosimilars Revenue by Manufacturers 3.2.1 Biosimilars Revenue by Manufacturers (2016-2018) 3.2.2 Biosimilars Revenue Share by Manufacturers (2016-2018) 3.3 Biosimilars Price by Manufacturers 3.4 Biosimilars Manufacturing Base Distribution, Product Types 3.4.1 Biosimilars Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Biosimilars Product Category 3.4.3 Date of International Manufacturers Enter into Biosimilars Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type 4.1 Global Biosimilars Sales by Type 4.2 Global Biosimilars Revenue by Type 4.3 Biosimilars Price by Type 5 Breakdown Data by Application 5.1 Overview 5.2 Global Biosimilars Breakdown Data by Application 6 North America 6.1 North America Biosimilars by Countries 6.1.1 North America Biosimilars Sales by Countries 6.1.2 North America Biosimilars Revenue by Countries 6.1.3 United States 6.1.4 Canada 6.1.5 Mexico 6.2 North America Biosimilars by Type 6.3 North America Biosimilars by Application 6.4 North America Biosimilars by Company 7 Europe 7.1 Europe Biosimilars by Countries 7.1.1 Europe Biosimilars Sales by Countries 7.1.2 Europe Biosimilars Revenue by Countries 7.1.3 Germany 7.1.4 France 7.1.5 UK 7.1.6 Italy 7.1.7 Russia 7.2 Europe Biosimilars by Type 7.3 Europe Biosimilars by Application 7.4 Europe Biosimilars by Company 8 Asia Pacific 8.1 Asia Pacific Biosimilars by Countries 8.1.1 Asia Pacific Biosimilars Sales by Countries 8.1.2 Asia Pacific Biosimilars Revenue by Countries 8.1.3 China 8.1.4 Japan 8.1.5 Korea 8.1.6 India 8.1.7 Australia 8.1.8 Indonesia 8.1.9 Malaysia 8.1.10 Philippines 8.1.11 Thailand 8.1.12 Vietnam 8.1.13 Singapore 8.2 Asia Pacific Biosimilars by Type 8.3 Asia Pacific Biosimilars by Application 8.4 Asia Pacific Biosimilars by Company 9 Central & South America 9.1 Central & South America Biosimilars by Countries 9.1.1 Central & South America Biosimilars Sales by Countries 9.1.2 Central & South America Biosimilars Revenue by Countries 9.1.3 Brazil 9.2 Central & South America Biosimilars by Type 9.3 Central & South America Biosimilars by Application 9.4 Central & South America Biosimilars by Company 10 Middle East and Africa 10.1 Middle East and Africa Biosimilars by Countries 10.1.1 Middle East and Africa Biosimilars Sales by Countries 10.1.2 Middle East and Africa Biosimilars Revenue by Countries 10.1.3 GCC Countries 10.1.4 Turkey 10.1.5 Egypt 10.1.6 South Africa 10.2 Middle East and Africa Biosimilars by Type 10.3 Middle East and Africa Biosimilars by Application 10.4 Middle East and Africa Biosimilars by Company 11 Company Profiles 11.1 Pfizer 11.1.1 Pfizer Company Details 11.1.2 Company Description 11.1.3 Sales, Revenue and Gross Margin of Biosimilars 11.1.4 Biosimilars Product Description 11.1.5 Recent Development 11.2 Sandoz International GmbH 11.2.1 Sandoz International GmbH Company Details 11.2.2 Company Description 11.2.3 Sales, Revenue and Gross Margin of Biosimilars 11.2.4 Biosimilars Product Description 11.2.5 Recent Development 11.3 Teva Pharmaceuticals Industries 11.3.1 Teva Pharmaceuticals Industries Company Details 11.3.2 Company Description 11.3.3 Sales, Revenue and Gross Margin of Biosimilars 11.3.4 Biosimilars Product Description 11.3.5 Recent Development 11.4 Amgen Inc 11.4.1 Amgen Inc Company Details 11.4.2 Company Description 11.4.3 Sales, Revenue and Gross Margin of Biosimilars 11.4.4 Biosimilars Product Description 11.4.5 Recent Development 11.5 Biocon 11.5.1 Biocon Company Details 11.5.2 Company Description 11.5.3 Sales, Revenue and Gross Margin of Biosimilars 11.5.4 Biosimilars Product Description 11.5.5 Recent Development 11.6 Dr. Reddy’s Laboratories 11.6.1 Dr. Reddy’s Laboratories Company Details 11.6.2 Company Description 11.6.3 Sales, Revenue and Gross Margin of Biosimilars 11.6.4 Biosimilars Product Description 11.6.5 Recent Development 11.7 F. Hoffmann-La Roche 11.7.1 F. Hoffmann-La Roche Company Details 11.7.2 Company Description 11.7.3 Sales, Revenue and Gross Margin of Biosimilars 11.7.4 Biosimilars Product Description 11.7.5 Recent Development 11.8 Celltrion 11.8.1 Celltrion Company Details 11.8.2 Company Description 11.8.3 Sales, Revenue and Gross Margin of Biosimilars 11.8.4 Biosimilars Product Description 11.8.5 Recent Development 11.9 Samsung Bioepis 11.9.1 Samsung Bioepis Company Details 11.9.2 Company Description 11.9.3 Sales, Revenue and Gross Margin of Biosimilars 11.9.4 Biosimilars Product Description 11.9.5 Recent Development 12 Market Opportunities, Challenges, Risks and Influences Factors Analysis 12.1 Market Opportunities and Drivers 12.2 Market Challenges 12.3 Market Risks/Restraints 12.4 Key World Economic Indicators 13 Value Chain and Sales Channels Analysis 13.1 Value Chain Analysis 13.1.1 Typical Suppliers of Key Biosimilars Raw Material 13.1.2 Biosimilars Customers 13.2 Sales Channels Analysis 13.2.1 Sales Channels Analysis 13.2.2 Distributors 14 Research Findings and Conclusion 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 188.8.131.52 Research Programs/Design 184.108.40.206 Market Size Estimation 220.127.116.11 Market Breakdown and Data Triangulation 15.1.2 Data Source 18.104.22.168 Secondary Sources 22.214.171.124 Primary Sources 15.2 Author Details 15.3 Disclaimer
Akasaka biz tower,
5-3-1 akasaka minato-ku,
13284 bluejacket street overland park,
KS 66213 United States